Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia
Authors:
- 1 August 2011
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 230 (2) , 227-239
Abstract
No abstract availableKeywords
Funding Information
- National Multiple Sclerosis Society
- Shriners Hospitals for Children
- National Institutes of Health (R01 ES015988, R01 NS059043)
This publication has 67 references indexed in Scilit:
- Enhanced Oligodendrogenesis and Recovery of Neurological Function by Erythropoietin After Neonatal Hypoxic/Ischemic Brain InjuryStroke, 2010
- Contributions of poly(ADP‐ribose) polymerase‐1 and ‐2 to nuclear translocation of apoptosis‐inducing factor and injury from focal cerebral ischemiaJournal of Neurochemistry, 2010
- Erythropoietin for infants with hypoxic–ischemic encephalopathyCurrent Opinion in Pediatrics, 2010
- Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte deathBrain, 2010
- Erythropoietin Sustains Cognitive Function and Brain Volume after Neonatal StrokeDevelopmental Neuroscience, 2009
- Brain injury in premature infants: a complex amalgam of destructive and developmental disturbancesThe Lancet Neurology, 2009
- Progress in Periventricular LeukomalaciaArchives of Neurology, 2008
- Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injuryAnnals of Neurology, 2008
- Pathogenesis of cerebral white matter injury of prematurityArchives of Disease in Childhood - Fetal and Neonatal Edition, 2008
- Post‐ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemiaBritish Journal of Pharmacology, 2007